公开(公告)号：US20240310386A1

公开(公告)日：2024-09-19

申请号：US18532159

申请日：2023-12-07

申请人： PHARMA CINQ, LLC

发明人： Jeffrey Allan MILLER ,  Eddie Phillip JEFFRIES

IPC分类号： G01N33/68 ,  C07K16/18 ,  G01N33/543

CPC分类号： G01N33/6893 ,  C07K16/18 ,  G01N33/54333 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/72 ,  G01N2333/4742 ,  G01N2510/00 ,  G01N2800/085 ,  G01N2800/7033

摘要： Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

公开(公告)号：US20240299434A1

公开(公告)日：2024-09-12

申请号：US18547777

申请日：2022-01-27

申请人： PHARMA CINQ. LLC

发明人： Michael Kevin BAMAT ,  Yi GAO ,  Jeffrey A. MILLER ,  Yihong QIU

IPC分类号： A61K31/7072 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K31/7072 ,  A61K47/32 ,  A61K47/38

摘要： There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability.

公开(公告)号：US20240342313A1

公开(公告)日：2024-10-17

申请号：US18622513

申请日：2024-03-29

申请人： Pharma Cinq, LLC

发明人： Tianci LUO ,  Daniel LIPUT ,  Fong Qi LIANG

IPC分类号： A61K48/00 ,  A61P27/02 ,  C07K14/47 ,  C12N9/02 ,  C12N15/86

CPC分类号： A61K48/0058 ,  A61K48/0083 ,  A61P27/02 ,  C07K14/47 ,  C12N9/0051 ,  C12N15/86 ,  C12Y108/01008 ,  C07K2319/02 ,  C07K2319/30 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2750/14171

摘要： The present invention relates to nucleic acids coding for and capable of expressing a full-length rod-derived cone viability factor (RdCVF) and human IgK signal sequence and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting a full-length RdCVF and human IgK signal sequence, and methods of treatment.

公开(公告)号：US12076367B2

公开(公告)日：2024-09-03

申请号：US17172202

申请日：2021-02-10

申请人： Pharma Cinq, LLC

发明人： Tianci Luo ,  Jun Zhang

IPC分类号： A61K38/17 ,  A61K47/42 ,  A61K47/64 ,  A61P25/14 ,  C07K14/47 ,  C07K14/76 ,  C12N9/02 ,  C12N15/11 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86

CPC分类号： A61K38/1709 ,  A61K47/42 ,  A61K47/643 ,  A61P25/14 ,  C07K14/47 ,  C07K14/76 ,  C12N9/0036 ,  C12N15/111 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86 ,  C12Y108/01008 ,  C07K2319/02 ,  C07K2319/31 ,  C12N2750/14143 ,  C12N2800/22

摘要： A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

公开(公告)号：US20240158431A1

公开(公告)日：2024-05-16

申请号：US18547053

申请日：2022-02-02

申请人： PHARMA CINQ, LLC

发明人： Reid Warren VON BORSTEL ,  David Michael SIMPSON ,  Rolando Alejandro GARCIA GARCIA

IPC分类号： C07H19/067 ,  A61K31/7072

CPC分类号： C07H19/067 ,  A61K31/7072

摘要： Compounds and compositions that deliver both uridine and ketoleucine are useful in treating disorders characterized by diminished muscle strength or diminished muscle lean mass. One such a compound is 5′-O-ketoleucyl-2′,3′-di-O-acetyluridine.